1Monash Health, Clayton, Victoria, Australia
2School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
3Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Parkville, Victoria, Australia
4Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia
5Department of Molecular Oncology and Cancer Immunology, Epworth Healthcare, East Melbourne, Victoria, Australia
6Research Division, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.
Correspondence: Gareth P. Gregory (. e-mail: firstname.lastname@example.org).
Citation: Gregory GP, Dickinson M, Yannakou CK, Wong J, Blombery P, Corboy G, Kats L, Crozier TME, Kumar B, Prince HM, Opat SS, Shortt J. Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS. HemaSphere, 2019;00:00. http://dx.doi.org/10.1097/HS9.0000000000000187
Gareth P. Gregory and Michael Dickinson co-first authors.
Stephen S. Opat and Jake Shortt co-senior authors.
All authors contributed to the writing of the manuscript and approved the final version. GPG, CKY, BK, PB and JW compiled the figures. CKY and PB performed the genomic analysis. GPG, JW, MD, TMEC, HMP, SSO and JS were all involved in the clinical management of the patient.
Disclosures: GPG: Celgene, research funding. MD: Celgene, research funding, honoraria. HMP: Celgene, advisory board, research funding. SSO: Celgene, advisory board. JS: Astex, research funding; Celgene, advisory board, speaker's bureau.
Azacitidine is not licensed in Australia for treatment of T-cell malignancies.
The panobinostat clinical trial was funded by a grant from the Victorian Cancer Agency (NCT01658241).
The authors have indicated they have no potential conflicts of interest to disclose.
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
Received December 2, 2018
Received in revised form January 23, 2019
Accepted February 10, 2019